Insulin Aspart (Novolog) Injectable Suppliers & Bulk Manufacturers
Available Forms: Vials/pens
Available Strengths: U-100, U-200
Reference Brands: Novolog, Fiasp(US &EU)
Category:
Diabetes
Insulin Aspart (Novolog) is a rapid-acting insulin that mimics natural insulin release after meals. It quickly lowers blood sugar levels, providing flexible timing for meals. Its benefits include rapid onset, precise glucose control, reduced post-meal hyperglycemia, and improved convenience for insulin therapy in both type 1 and type 2 diabetes management.
Insulin Aspart (Novolog) injectable is available in Vials/pens
and strengths such as U-100, U-200.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Insulin Aspart (Novolog) injectable is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Insulin Aspart (Novolog) injectable can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Insulin Aspart (Novolog) is a rapid-acting insulin approved in the EU and US for controlling blood glucose during meals. In the EU, Novo Nordisk’s Novolog and Fiasp are regulated by the EMA, with dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, the FDA has approved NovoLog and Fiasp based on comprehensive clinical data and biosimilarity studies, ensuring quality and consistency. Both regions require detailed regulatory dossiers and ongoing pharmacovigilance for safety monitoring. For expert assistance with regulatory dossiers and compliance, visit PharmaTradz, your trusted partner in pharmaceutical regulatory services.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing